{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:06:31Z","timestamp":1757311591785},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00059-022-05156-0","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T20:37:31Z","timestamp":1676061451000},"page":"159-168","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF)"],"prefix":"10.1007","volume":"48","author":[{"given":"Caroline","family":"Morbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"issue":"3","key":"5156_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt\u00a0B, Coats\u00a0AJS, Tsutsui\u00a0H et\u00a0al (2021) Universal definition and classification of heart failure: a\u00a0report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 23(3):352\u2013380. https:\/\/doi.org\/10.1002\/ejhf.2115","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"5156_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.483","volume":"18","author":"EE van Riet","year":"2016","unstructured":"van Riet\u00a0EE, Hoes\u00a0AW, Wagenaar\u00a0KP et\u00a0al (2016) Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 18(3):242\u2013252. https:\/\/doi.org\/10.1002\/ejhf.483","journal-title":"Eur J Heart Fail"},{"key":"5156_CR3","doi-asserted-by":"publisher","first-page":"104369","DOI":"10.1016\/j.ebiom.2022.104369","volume":"86","author":"A Schulz","year":"2022","unstructured":"Schulz\u00a0A, Schuster\u00a0A (2022) Visualizing diastolic failure: non-invasive imaging-biomarkers in patients with heart failure with preserved ejection fraction. eBioMedicine 86:104369. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104369","journal-title":"eBioMedicine"},{"issue":"3","key":"5156_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan\u00a0TE, Hodge\u00a0DO, Herges\u00a0RM et\u00a0al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N\u00a0Engl J Med 355(3):251\u2013259. https:\/\/doi.org\/10.1056\/NEJMoa052256","journal-title":"N Engl J Med"},{"issue":"8","key":"5156_CR5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","volume":"6","author":"CW Tsao","year":"2018","unstructured":"Tsao\u00a0CW, Lyass\u00a0A, Enserro\u00a0D et\u00a0al (2018) Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 6(8):678\u2013685. https:\/\/doi.org\/10.1016\/j.jchf.2018.03.006","journal-title":"JACC Heart Fail"},{"issue":"36","key":"5156_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"issue":"18","key":"5156_CR7","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich\u00a0PA, Bozkurt\u00a0B, Aguilar\u00a0D et\u00a0al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"issue":"6","key":"5156_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00108-019-0606-7","volume":"60","author":"K Hellenkamp","year":"2019","unstructured":"Hellenkamp\u00a0K, von Haehling\u00a0S (2019) The relevance of biomarkers in acute heart failure. Internist 60(6):587\u2013596. https:\/\/doi.org\/10.1007\/s00108-019-0606-7","journal-title":"Internist"},{"issue":"9","key":"5156_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy\u00a0YNV, Carter\u00a0RE, Obokata\u00a0M et al (2018) A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138(9):861\u2013870. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034646","journal-title":"Circulation"},{"issue":"40","key":"5156_CR10","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske\u00a0B, Tschope\u00a0C, de Boer\u00a0RA et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a\u00a0consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart\u00a0J 40(40):3297\u20133317. https:\/\/doi.org\/10.1093\/eurheartj\/ehz641","journal-title":"Eur Heart J"},{"issue":"4","key":"5156_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/ehf2.12458","volume":"6","author":"U Lofstrom","year":"2019","unstructured":"Lofstrom\u00a0U, Hage\u00a0C, Savarese\u00a0G et\u00a0al (2019) Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. ESC Heart Fail 6(4):830\u2013839. https:\/\/doi.org\/10.1002\/ehf2.12458","journal-title":"ESC Heart Fail"},{"issue":"26","key":"5156_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","volume":"285","author":"PA McKee","year":"1971","unstructured":"McKee\u00a0PA, Castelli\u00a0WP, McNamara\u00a0PM et\u00a0al (1971) The natural history of congestive heart failure: the Framingham study. N\u00a0Engl J Med 285(26):1441\u20131446. https:\/\/doi.org\/10.1056\/NEJM197112232852601","journal-title":"N Engl J Med"},{"issue":"6","key":"5156_CR13","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cardfail.2021.12.013","volume":"28","author":"J Vaishnav","year":"2022","unstructured":"Vaishnav\u00a0J, Sharma\u00a0K (2022) A stepwise guide to the diagnosis and treatment of heart failure with preserved ejection fraction. J\u00a0Card Fail 28(6):1016\u20131030. https:\/\/doi.org\/10.1016\/j.cardfail.2021.12.013","journal-title":"J Card Fail"},{"issue":"3","key":"5156_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.120.050757","volume":"143","author":"TW Churchill","year":"2021","unstructured":"Churchill\u00a0TW, Li\u00a0SX, Curreri\u00a0L et\u00a0al (2021) Evaluation of 2 existing diagnostic scores for heart failure with preserved ejection fraction against a\u00a0comprehensively phenotyped cohort. Circulation 143(3):289\u2013291. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050757","journal-title":"Circulation"},{"issue":"15","key":"5156_CR15","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.120.051542","volume":"143","author":"SJ Backhaus","year":"2021","unstructured":"Backhaus\u00a0SJ, Lange\u00a0T, George\u00a0EF et al (2021) Exercise stress real-time cardiac magnetic resonance imaging for noninvasive characterization of heart failure with preserved ejection fraction: the HFpEF-stress trial. Circulation 143(15):1484\u20131498. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051542","journal-title":"Circulation"},{"issue":"10253","key":"5156_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto\u00a0I, Oreziak\u00a0A, Barriales-Villa\u00a0R et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a\u00a0randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759\u2013769. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X","journal-title":"Lancet"},{"issue":"4","key":"5156_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/vox.12896","volume":"115","author":"CR Murphree","year":"2020","unstructured":"Murphree\u00a0CR, Nguyen\u00a0NN, Raghunathan\u00a0V et\u00a0al (2020) Diagnosis and management of hereditary haemochromatosis. Vox Sang 115(4):255\u2013262. https:\/\/doi.org\/10.1111\/vox.12896","journal-title":"Vox Sang"},{"issue":"7","key":"5156_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni\u00a0M, Moon\u00a0JC, Arbustini\u00a0E et\u00a0al (2021) Cardiac involvement in Fabry disease: JACC review topic of the week. J\u00a0Am Coll Cardiol 77(7):922\u2013936. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.024","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"5156_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","volume":"110","author":"A Yilmaz","year":"2021","unstructured":"Yilmaz\u00a0A, Bauersachs\u00a0J, Bengel\u00a0F et\u00a0al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 110(4):479\u2013506. https:\/\/doi.org\/10.1007\/s00392-020-01799-3","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"5156_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","volume":"4","author":"AD Wechalekar","year":"2022","unstructured":"Wechalekar\u00a0AD, Fontana\u00a0M, Quarta\u00a0C et\u00a0al (2022) AL amyloidosis for cardiologists. Jacc Cardio Oncol 4(4):427\u2013441. https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.009","journal-title":"Jacc Cardio Oncol"},{"issue":"6","key":"5156_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jchf.2015.01.009","volume":"3","author":"DW Kitzman","year":"2015","unstructured":"Kitzman\u00a0DW, Upadhya\u00a0B, Reeves\u00a0G (2015) Hospitalizations and prognosis in elderly patients with heart failure and preserved ejection fraction: time to treat the whole patient. JACC Heart Fail 3(6):442\u2013444. https:\/\/doi.org\/10.1016\/j.jchf.2015.01.009","journal-title":"JACC Heart Fail"},{"issue":"1","key":"5156_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1161\/CIRCHEARTFAILURE.114.001615","volume":"8","author":"A Pandey","year":"2015","unstructured":"Pandey\u00a0A, Parashar\u00a0A, Kumbhani\u00a0D et al (2015) Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail 8(1):33\u201340. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001615","journal-title":"Circ Heart Fail"},{"issue":"3","key":"5156_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2026141","volume":"385","author":"DW Kitzman","year":"2021","unstructured":"Kitzman\u00a0DW, Whellan\u00a0DJ, Duncan\u00a0P et\u00a0al (2021) Physical rehabilitation for older patients hospitalized for heart failure. N\u00a0Engl J Med 385(3):203\u2013216. https:\/\/doi.org\/10.1056\/NEJMoa2026141","journal-title":"N Engl J Med"},{"issue":"9766","key":"5156_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","volume":"377","author":"WT Abraham","year":"2011","unstructured":"Abraham\u00a0WT, Adamson\u00a0PB, Bourge\u00a0RC et\u00a0al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a\u00a0randomised controlled trial. Lancet 377(9766):658\u2013666. https:\/\/doi.org\/10.1016\/S0140-6736(11)60101-3","journal-title":"Lancet"},{"issue":"10","key":"5156_CR25","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.1943","volume":"22","author":"CE Angermann","year":"2020","unstructured":"Angermann\u00a0CE, Assmus\u00a0B, Anker\u00a0SD et al (2020) Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). Eur J Heart Fail 22(10):1891\u20131901. https:\/\/doi.org\/10.1002\/ejhf.1943","journal-title":"Eur J Heart Fail"},{"key":"5156_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101349","author":"FR Prandi","year":"2022","unstructured":"Prandi\u00a0FR, Barone\u00a0L, Lecis\u00a0D et al (2022) Biomolecular mechanisms of cardiorenal protection with sodium-glucose co-transporter 2 inhibitors. Biomolecules. https:\/\/doi.org\/10.3390\/biom12101349","journal-title":"Biomolecules"},{"issue":"21","key":"5156_CR27","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1056\/NEJMc2118470","volume":"386","author":"SD Anker","year":"2022","unstructured":"Anker\u00a0SD, Butler\u00a0J, Packer\u00a0M (2022) Empagliflozin in heart failure with a\u00a0preserved ejection fraction. N\u00a0Engl J Med 386(21):e57. https:\/\/doi.org\/10.1056\/NEJMc2118470 (Reply)","journal-title":"N Engl J Med"},{"issue":"12","key":"5156_CR28","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Claggett\u00a0B et\u00a0al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N\u00a0Engl J Med 387(12):1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"issue":"10354","key":"5156_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan\u00a0M, Docherty\u00a0KF, Claggett\u00a0BL et al (2022) SGLT\u20112 inhibitors in patients with heart failure: a\u00a0comprehensive meta-analysis of five randomised controlled trials. Lancet 400(10354):757\u2013767. https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5","journal-title":"Lancet"},{"issue":"15","key":"5156_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stefansson\u00a0BV, Correa-Rotter\u00a0R et al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"5156_CR31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","author":"WG Herrington","year":"2022","unstructured":"Group E\u2011KC, Herrington\u00a0WG, Staplin\u00a0N et al (2022) Empagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"issue":"11","key":"5156_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink\u00a0HJL, Jongs\u00a0N, Chertow\u00a0GM et al (2021) Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a\u00a0prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9(11):743\u2013754. https:\/\/doi.org\/10.1016\/S2213-8587(21)00242-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5156_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.4348","author":"KM Talha","year":"2022","unstructured":"Talha\u00a0KM, Butler\u00a0J, Greene\u00a0SJ et al (2022) Population-level implications of sodium-glucose cotransporter\u20112 inhibitors for heart failure with preserved ejection fraction in the US. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2022.4348","journal-title":"JAMA Cardiol"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-022-05156-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T16:03:10Z","timestamp":1678896190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-022-05156-0"}},"subtitle":["Diagnose und Therapie"],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["5156"],"URL":"https:\/\/doi.org\/10.1007\/s00059-022-05156-0","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"14 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>C.\u00a0Morbach<\/b>: 1)\u00a0Forschungskooperation mit Universit\u00e4t W\u00fcrzburg und Tomtec Imaging Systems gef\u00f6rdert im Rahmen des Masterplans Bayern digital\u00a0II; 2)\u00a0Speakers bureau\/travel grant\/advisory board\/patient eligibility board von Amgen, Tomtec, Orion Pharma, Alnylam, AKCEA, SOBI, Pfizer, Boehringer Ingelheim, Novo Nordisk, Alexion, Janssen und EBR Systems; 3)\u00a0Principal Investigator in Studien von Alnylam, AstraZeneca und Bayer; 4)\u00a0F\u00f6rderung durch das Interdisziplin\u00e4re Zentrum f\u00fcr Klinische Forschung\u00a0\u2013 IZKF W\u00fcrzburg (Advanced Clinician-Scientist Programm). <b>S.\u00a0St\u00f6rk<\/b>: 1)\u00a0BMBF #01EO1004 und #01EO1504; Gemeinsamer Bundesausschuss: Erprobungsstudie zum Telemonitoring mittels pulmonalarteriellen Drucksensors. 2)\u00a0Studienleiter in Studien von bzw. Referent oder Advisor f\u00fcr: AKCEA, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytogenetics, IONIS, MSD, Novartis, Orion Pharma, Pfizer, Pharmacosmos, Sanofi, Servier, SOBI.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}